This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
For informational purposes only — not medical advice
How serious?
Risk of death
Yes
Vaccine available?
Time to symptoms
Countries affected
Active outbreaks
Measles is highly contagious and outbreaks occur worldwide. Verify your MMR vaccination status before travel (2 doses required). Unvaccinated travelers are at significant risk in crowded settings. Post-exposure vaccination within 72 hours can prevent illness.
Highly contagious viral disease causing fever, rash, and respiratory symptoms. One of the most infectious pathogens known to science (R0 = 12–18).
Symptoms | Frequency | Severity | Onset |
|---|---|---|---|
| Koplik spots | 70% | Mild | Early |
| Conjunctivitis | 92% | Mild | Early |
| Cough | 95% | Mild | Early |
| High fever | 98% | Severe | Early |
| Malaise | 85% | Mild | Early |
| Rhinorrhea | 90% | Mild | Early |
| Headache | 50% | Mild | Early |
| Irritability | 60% | Mild | Early |
| Excessive tearing | 60% | Mild | Early |
| Loss of appetite | 70% | Mild | Early |
| Photophobia | 50% | Mild | Early |
| Myalgia | 35% | Mild | Early |
| Sore throat | 40% | Mild | Early |
| Maculopapular rash | 99% | Mild | Peak |
| Swollen lymph nodes | 50% | Mild | Peak |
| Abdominal pain | 20% | Mild | Peak |
| Diarrhea | 8% | Mild | Peak |
| Vomiting | 15% | Mild | Peak |
| Fatigue | 80% | Mild | Any phase |
Measles is a highly contagious viral disease caused by the measles virus (morbillivirus). It remains one of the most communicable infectious diseases, with a reproduction number (R₀) of approximately 12-18, meaning one infected person can spread the virus to up to 18 others in an unvaccinated population. Despite being vaccine-preventable, measles continues to pose risks to travelers visiting regions with lower vaccination coverage.
Measles spreads through:
Airborne droplets: When an infected person coughs or sneezes
Direct contact: With respiratory secretions from infected individuals
High transmissibility: The virus remains infectious in air for up to 2 hours after an infected person leaves a room
Travelers to regions with active measles outbreaks face significant risk, particularly those who are:
Unvaccinated or partially vaccinated
Traveling with unvaccinated children
Born after 1957 without documented vaccination
Incubation Period: 7-21 days (average 10 days)
Classic Presentation (3-phase progression):
Severity: Measles typically causes more severe illness than many other vaccine-preventable diseases, with complications occurring in 1 out of every 4 infected children.
Serious complications occur in approximately 1-2 per 1,000 infected individuals:
Pneumonia (most common complication, ~7% of cases)
Encephalitis (brain inflammation, ~0.1% of cases)
Subacute Sclerosing Panencephalitis (SSPE): Rare but fatal degenerative brain disease occurring 7-10 years after infection
Secondary infections: Otitis media, sinusitis
Mortality: 0.2% in developed countries; up to 10% in low-resource settings with malnutrition
Vaccine Effectiveness:
1 dose: ~95% effective
2 doses: >99% effective
Immunity: Lifelong for vaccinated individuals
Recommended Vaccination:
2 doses of MMR vaccine (measles, mumps, rubella)
First dose: 12-15 months
Second dose: 4-6 years or any time ≥28 days after first dose
Adults born 1957 or later should have ≥2 documented doses or serological proof of immunity
Pre-Travel Considerations:
Verify immunity 4-6 weeks before travel
Request revaccination if immunity status is uncertain
Immunocompromised individuals should consult healthcare providers before vaccination
High-risk destinations: Sub-Saharan Africa, parts of Asia, pockets of low vaccination coverage in developed countries
Outbreak awareness: Check WHO travel advisories and local health departments for current measles activity
Post-exposure guidance: If exposed to measles, vaccinated or unvaccinated individuals should seek medical evaluation immediately
Isolation protocol: Infected travelers should remain isolated for 4 days after rash onset to prevent further transmission
Seek immediate medical attention if experiencing:
High fever (>40°C/104°F) not responding to antipyretics
Difficulty breathing or chest pain
Severe headache or sensitivity to light
Confusion or altered consciousness
Signs of dehydration (no urination for >6 hours, severe thirst)
Diagnosis: Clinical presentation + PCR testing, serology, or viral culture
Treatment: Supportive care (no specific antiviral); vitamin A supplementation recommended
Reportable disease: Measles is notifiable to health authorities in most countries
Causative Agent: Measles morbillivirus
ICD-10 Code: B05
ICD-11 Code: 1F03
Incubation Period: 7-21 days
Infectious Period: 4 days before rash to 4 days after rash onset
Mortality Rate: 0.2-10% depending on healthcare access
Vaccine-Preventable: Yes (highly effective)
Notifiable Disease: Yes (mandatory reporting)
Measles is caused by Measles morbillivirus transmitted via airborne droplets. It remains a leading preventable cause of child mortality in low-vaccination regions despite a highly effective vaccine available since 1963.
Seek emergency medical care immediately if:
Difficulty breathing, rapid breathing, or grunting
Severe headache, neck stiffness, or altered consciousness (encephalitis)
Seizures or convulsions
Inability to drink or persistent vomiting
Signs of severe dehydration (sunken eyes, no urination, extreme lethargy)
Rash that becomes purple or looks like bruising (may indicate secondary infection)
Most common signs and symptoms
The disease progresses through two clinical phases:
Prodromal phase (2–4 days): High fever (up to 40°C/104°F), persistent cough, coryza (runny nose), and conjunctivitis — the classic "3 Cs". Koplik's spots (small bluish-white lesions on the inner cheeks) are pathognomonic and appear 1–2 days before the rash.
Exanthem phase (4–7 days): Characteristic maculopapular rash begins at the hairline and spreads cephalocaudally to the trunk and extremities over 3 days. Fever peaks at rash onset. Lymphadenopathy and splenomegaly may occur.
Knowing the symptoms is the first step to a quick response.
Typical disease course:
Infectivity: From 4 days before to 4 days after rash onset. Most contagious during prodromal phase. Basic reproduction number (R₀): 12–18 (one of the most transmissible human pathogens).
How this disease is identified
Clinical diagnosis is supported by the characteristic rash pattern and Koplik's spots in an unvaccinated individual with fever and the 3 Cs. Laboratory confirmation:
Serology: IgM antibody detection (positive 3 days after rash onset) — most practical
RT-PCR: from nasopharyngeal swab, urine, or blood — most sensitive, confirms genotype
Throat or urine culture: reference labs only Mandatory public health notification required in most countries.
Available treatment methods
No specific antiviral therapy exists for measles. Management is supportive:
Vitamin A supplementation: WHO recommends 200,000 IU on 2 consecutive days for children with measles — reduces mortality and complications by up to 50%
Antipyretics (paracetamol/ibuprofen) for fever management
Adequate hydration and nutrition support
Secondary bacterial infection (otitis media, pneumonia): antibiotics as appropriate
Hospitalization for complicated cases (encephalitis, pneumonia, severe dehydration)
Ribavirin has been used in immunocompromised patients (off-label)
Most cases are effectively treated with early diagnosis.
How to protect yourself
The MMR (Measles-Mumps-Rubella) vaccine provides >97% protection after two doses:
Dose 1: 12–15 months of age
Dose 2: 4–6 years of age (or at least 28 days after Dose 1)
Post-exposure prophylaxis: MMR within 72 hours of exposure in susceptible individuals; immunoglobulin within 6 days for high-risk contacts (infants <12 months, immunocompromised, pregnant women)
Herd immunity threshold: ~95% vaccine coverage required to prevent outbreaks WHO recommends 2-dose schedule for all children. Travelers to endemic regions should ensure vaccination is up to date.
Preparation is the best protection.
Risk to travelers:
High risk: Sub-Saharan Africa, parts of Asia, Pacific Islands during outbreaks. Moderate risk globally due to resurgence in Europe and North America.
Ensure 2 doses of MMR vaccine before travel, regardless of destination.
Infants traveling to high-risk areas may receive MMR from 6 months (does not count toward primary schedule — revaccinate at 12–15 months).
In outbreak settings, avoid crowded indoor spaces; measles spreads in airborne particles that linger up to 2 hours after an infected person leaves.
Report suspected measles immediately to local health authorities.
Statistics and geographic data
Globally, measles affects millions annually. WHO reported ~9 million cases and ~128,000 deaths in 2021, predominantly in children <5. Major outbreaks occurred 2018–2019 in Democratic Republic of Congo, Madagascar, Ukraine, Philippines, and USA. Africa and Southeast Asia carry the highest burden. Europe has experienced resurgence due to vaccine hesitancy. The R0 of 12–18 makes measles the most infectious respiratory pathogen known. Global coverage with 2-dose MCV2 reached 71% in 2021 (WHO target: 90%).
Who is most at risk
Risk factors for acquiring measles:
Lack of vaccination: The single most important risk factor. Unvaccinated individuals have a >90% chance of infection after exposure to the virus. Even one missed dose leaves a 7% susceptibility gap.
International travel to endemic regions (sub-Saharan Africa, South/Southeast Asia, parts of Europe) without verified immunity.
Crowded living conditions: Refugee camps, dormitories, military barracks, and densely populated urban areas facilitate rapid transmission.
Healthcare settings: Nosocomial transmission is well-documented; the virus can linger in examination rooms for 2 hours after an infectious patient has left.
Waning maternal antibodies: Infants aged 6–12 months lose maternally acquired protection and are not yet routinely vaccinated.
Community under-vaccination: Localized pockets of low vaccination coverage (religious communities, areas with vaccine hesitancy) serve as outbreak epicenters.
Risk factors for severe disease and complications:
Age extremes: Children under 5 years and adults over 20 years have the highest complication and mortality rates.
Malnutrition: Particularly vitamin A deficiency, which increases the risk of corneal damage, severe pneumonia, and death by 2–3 fold.
Immunocompromised status: HIV/AIDS, active chemotherapy, organ transplant recipients, and congenital immunodeficiencies. These patients may develop giant cell pneumonia (Hecht pneumonia) or measles inclusion body encephalitis (MIBE).
Pregnancy: Measles during pregnancy increases risk of spontaneous abortion, premature delivery, and low birth weight.
Overcrowding and poor access to healthcare: Delayed diagnosis and treatment significantly worsen outcomes.
Potential complications
Complications are more severe in infants, malnourished individuals, immunocompromised patients, and pregnant women:
Otitis media: most common complication (1 in 10 cases)
Pneumonia: leading cause of measles death (1 in 20 cases)
may be viral or secondary bacterial
Diarrhea and dehydration: especially dangerous in developing countries
Encephalitis: 1 in 1,000 cases
15% mortality, 25% long-term neurological sequelae
Subacute sclerosing panencephalitis (SSPE): rare, fatal, progressive neurological disease appearing 7–10 years after infection (approximately 1 in 10,000 cases overall
1 in 1,700–5,000 when infected before age 5)
Blindness: due to vitamin A deficiency exacerbated by measles
Immunosuppression: measles causes "immune amnesia," deleting immunological memory for months to years
Expected outcomes and recovery
Overall prognosis: Favorable in well-nourished individuals with access to supportive care. Case-fatality rate (CFR) is <0.1% in high-income countries but 3–6% in resource-limited settings, rising to 25% in malnourished children and displaced populations.
Complications affecting prognosis:
Pneumonia (most common cause of measles death): 1–6% of cases.
Encephalitis: ~1 in 1,000 cases; 15% fatality, 25% permanent neurological sequelae.
Subacute sclerosing panencephalitis (SSPE): fatal degenerative CNS disease, onset 7–10 years after infection. Incidence: ~1 in 10,000 measles cases (higher if infected before age 2).
Immune amnesia: measles destroys 11–73% of existing antibody repertoire, increasing susceptibility to other infections for 2–3 years post-recovery.
Recovery: Most uncomplicated cases resolve fully within 7–10 days. Lifelong immunity after natural infection.
This disease is vaccine-preventable. Effective protection is available through vaccination.
Talk to a travel health specialist about the recommended schedule before your trip.
Find a vaccination clinic →The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.
Full terms of useRecent epidemiological data from the World Health Organization Global Health Observatory.
Source: WHO GHO OData ↗
And 15 more records
This data is provided for informational purposes. Please consult official WHO sources for the most current information.
View WHO data source →Know which vaccine you need? Great. Not sure? Just tell us your destination — we will figure it out and match you with a clinic. Free, no obligation.